Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Aims To investigate the impact of patiromer on the serum potassium level and its ability to
enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) …

Novel pharmacologic treatment options reduce mortality and morbidity in a cost‐effective
manner in patients with heart failure (HF). Undisputedly, the effective implementation of …

Aims Use and dosing of guideline‐directed medical therapy (GDMT) in patients with heart
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

Aim Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their
pharmacological management. We evaluated physicians' and patients' patterns of use of …

Aims This prespecified analysis of the FIDELIO‐DKD trial compared the effects of
finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal …

Abstract Aim In the EMPEROR‐Preserved trial, empagliflozin improved clinical outcomes of
patients with heart failure (HF) with preserved ejection fraction. In this pre‐specified analysis …